Scott M. Dehm
About Scott M. Dehm
Dr. Dehm completed a BS and PhD in Biochemistry at the University of Saskatchewan and has been a Postdoctoral Fellow working with Don Tindall at the Mayo Clinic. Dr. Tindall is a leading expert on the function of the androgen receptor. Dr. Dehm is currently an Assistant Professor at the University of Minnesota.
In the event that surgery or radiation does not curtail prostate cancer, locally recurrent or metastatic disease may be treated via a systemic blockade of the production or action of androgens. This so-called androgen ablation therapy specifically inhibits the androgen receptor (AR), a receptor that drives the proliferation and survival of prostate cancer. However, androgen ablation is not curative, and prostate cancer can invariably progress. Novel modes of AR inhibition are needed to study advanced prostate cancer. The goal of this proposal is to create models that reflect how AR continues to cause proliferation and survival of prostate cancer even after androgen synthesis and activity are blocked.
Dr. Dehm’s mentors at the Masonic Cancer Center, University of Minnesota will be Kenneth Koeneman, MD, a urology specialist, and James McCarthy, PhD, who focuses on prostate cancer tumor biology and leads the Tumor Biology and Progression Research Program at the cancer center.
The 2008 Kovler Family Foundation – PCF Young Investigator Award
Scott M. Dehm, PhD
Masonic Cancer Center, University of Minnesota – Minneapolis, MN